middle.news
Opthea Secures A$10.8M Boost for Sozinibercept R&D Progress
8:44am on Monday 6th of October, 2025 AEDT
•
Healthcare
Read Story
Opthea Secures A$10.8M Boost for Sozinibercept R&D Progress
8:44am on Monday 6th of October, 2025 AEDT
Key Points
A$10.8 million R&D tax incentive awarded for 2024/2025 fiscal year
Incentive supports development of drug candidate sozinibercept
Funding reflects both Australian and eligible overseas R&D expenditures
Opthea emphasizes fiscal discipline alongside innovation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Opthea (ASX:OPT)
OPEN ARTICLE